Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Aerodynamical, immunological and pharmacological properties of the anticancer antibody cetuximab following nebulization.

Maillet A, Congy-Jolivet N, Le Guellec S, Vecellio L, Hamard S, Courty Y, Courtois A, Gauthier F, Diot P, Thibault G, Lemarié E, Heuzé-Vourc'h N.

Pharm Res. 2008 Jun;25(6):1318-26.

PMID:
18030605
2.

The airways, a novel route for delivering monoclonal antibodies to treat lung tumors.

Maillet A, Guilleminault L, Lemarié E, Lerondel S, Azzopardi N, Montharu J, Congy-Jolivet N, Reverdiau P, Legrain B, Parent C, Douvin DH, Hureaux J, Courty Y, De Monte M, Diot P, Paintaud G, Le Pape A, Watier H, Heuzé-Vourc'h N.

Pharm Res. 2011 Sep;28(9):2147-56. doi: 10.1007/s11095-011-0442-5. Epub 2011 Apr 14.

PMID:
21491145
3.

Physicochemical aspects and efficiency of albuterol nebulization: comparison of three aerosol types in an in vitro pediatric model.

Sidler-Moix AL, Di Paolo ER, Dolci U, Berger-Gryllaki M, Cotting J, Pannatier A.

Respir Care. 2015 Jan;60(1):38-46. doi: 10.4187/respcare.02490. Epub 2014 Dec 16.

4.

Albuterol delivery in an in vitro pediatric ventilator lung model: comparison of jet, ultrasonic, and mesh nebulizers.

Sidler-Moix AL, Dolci U, Berger-Gryllaki M, Pannatier A, Cotting J, Di Paolo ER.

Pediatr Crit Care Med. 2013 Feb;14(2):e98-102. doi: 10.1097/PCC.0b013e3182712783.

PMID:
23287904
5.

Physical stability and aerosol properties of liposomes delivered using an air-jet nebulizer and a novel micropump device with large mesh apertures.

Elhissi AM, Faizi M, Naji WF, Gill HS, Taylor KM.

Int J Pharm. 2007 Apr 4;334(1-2):62-70. Epub 2006 Oct 21.

PMID:
17123757
6.

PAMAM dendrimers as aerosol drug nanocarriers for pulmonary delivery via nebulization.

Nasr M, Najlah M, D'Emanuele A, Elhissi A.

Int J Pharm. 2014 Jan 30;461(1-2):242-50. doi: 10.1016/j.ijpharm.2013.11.023. Epub 2013 Nov 22.

PMID:
24275446
7.

Design principles of liquid nebulization devices currently in use.

Rau JL.

Respir Care. 2002 Nov;47(11):1257-75; discussion 1275-8. Review.

PMID:
12425742
8.

The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.

Raben D, Helfrich B, Chan DC, Ciardiello F, Zhao L, Franklin W, Barón AE, Zeng C, Johnson TK, Bunn PA Jr.

Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):795-805.

9.

Formulations generated from ethanol-based proliposomes for delivery via medical nebulizers.

Elhissi AM, Karnam KK, Danesh-Azari MR, Gill HS, Taylor KM.

J Pharm Pharmacol. 2006 Jul;58(7):887-94.

PMID:
16805947
10.

Delivery of glucocorticoids by jet nebulization: aerosol characteristics and output.

Leflein J, Brown E, Hill M, Kelly HW, Loffert DT, Nelson HS, Szefler SJ.

J Allergy Clin Immunol. 1995 May;95(5 Pt 1):944-9.

PMID:
7751514
11.

Inhalation of tobramycin in cystic fibrosis. Part 1: the choice of a nebulizer.

Le Brun PP, de Boer AH, Gjaltema D, Hagedoorn P, Heijerman HG, Frijlink HW.

Int J Pharm. 1999 Nov 5;189(2):205-14.

PMID:
10536249
12.

Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.

Harding J, Burtness B.

Drugs Today (Barc). 2005 Feb;41(2):107-27. Review.

PMID:
15821783
13.

Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk.

Yoshida T, Okamoto I, Okabe T, Iwasa T, Satoh T, Nishio K, Fukuoka M, Nakagawa K.

Int J Cancer. 2008 Apr 1;122(7):1530-8.

14.

Jet and ultrasonic nebulization of single chain urokinase plasminogen activator (scu-PA).

Münster AM, Bendstrup E, Jensen JI, Gram J.

J Aerosol Med. 2000 Winter;13(4):325-33.

PMID:
11262439
15.

[Benefits of nebulized therapy: basic concepts].

Máiz Carro L, Wagner Struwing C.

Arch Bronconeumol. 2011 Jun;47 Suppl 6:2-7. doi: 10.1016/S0300-2896(11)70028-X. Spanish.

16.

Ultrasonic nebulization of cationic lipid-based gene delivery systems for airway administration.

Pillai R, Petrak K, Blezinger P, Deshpande D, Florack V, Freimark B, Padmabandu G, Rolland A.

Pharm Res. 1998 Nov;15(11):1743-7.

PMID:
9833997
17.

In Vitro Comparison of a Vibrating Mesh Nebulizer Operating in Inspiratory Synchronized and Continuous Nebulization Modes During Noninvasive Ventilation.

Michotte JB, Staderini E, Le Pennec D, Dugernier J, Rusu R, Roeseler J, Vecellio L, Liistro G, Reychler G.

J Aerosol Med Pulm Drug Deliv. 2016 Aug;29(4):328-36. doi: 10.1089/jamp.2015.1243. Epub 2016 Jun 16.

PMID:
27310926
18.

Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.

Huang S, Armstrong EA, Benavente S, Chinnaiyan P, Harari PM.

Cancer Res. 2004 Aug 1;64(15):5355-62.

19.
20.

Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study.

Ramalingam S, Forster J, Naret C, Evans T, Sulecki M, Lu H, Teegarden P, Weber MR, Belani CP.

J Thorac Oncol. 2008 Mar;3(3):258-64. doi: 10.1097/JTO.0b013e3181653d1b.

Supplemental Content

Support Center